TRIMTECH Therapeutics lands an £11m seed extension led by JJDC and BGF to degrade toxic proteins linked to Alzheimer's and other neurodegenerative diseases

TRIMTECH Therapeutics is a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases. Its TRIMTAC and TRIMGLUE platforms are designed to selectively degrade toxic protein aggregates and oligomers whilst leaving functional monomeric forms of those proteins intact to support healthy cellular function.